Levi & Korsinsky announces it has commenced an investigation of Seres Therapeutics, Inc. (NASDAQGS: MCRB) (“Seres”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On July 29, 2016, the Company announced that its Phase 2 clinical study for ECOSPOR did not meet its primary endpoint. Following this news, Seres shares opened trading down 76% on August 1, 2016. Two days before the announcement, on July 27, 2016, Seres’ President, Chief Executive Officer, and Chairman of the Board sold 20,000 shares at $35 per share for gross proceeds of $700,000. To obtain additional information, go to:

http://zlk.9nl.com/seres-therapeutics-mcrb

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160801006074/en/